Logo image of MLND

Millendo Therapeutics Inc (MLND) Stock Fundamental Analysis

USA - NASDAQ:MLND -

1.06
-0.06 (-5.36%)
Last: 6/25/2021, 8:00:01 PM
1.06
0 (0%)
After Hours: 6/25/2021, 8:00:01 PM
Fundamental Rating

2

Overall MLND gets a fundamental rating of 2 out of 10. We evaluated MLND against 533 industry peers in the Biotechnology industry. The financial health of MLND is average, but there are quite some concerns on its profitability. MLND has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MLND had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -103.44%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MLND does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

MLND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -11.67, we must say that MLND is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for MLND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.67
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 6.39 indicates that MLND has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 6.39
Quick Ratio N/A

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.73% over the past year.
EPS 1Y (TTM)44.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MLND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.92% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.23%
EPS Next 2Y32.4%
EPS Next 3Y23.27%
EPS Next 5Y17.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MLND Yearly Revenue VS EstimatesMLND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2023 2024 0 -2000Q -4000Q -6000Q -8000Q
MLND Yearly EPS VS EstimatesMLND Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MLND. In the last year negative earnings were reported.
Also next year MLND is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLND Price Earnings VS Forward Price EarningsMLND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.22
MLND Per share dataMLND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as MLND's earnings are expected to grow with 23.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.4%
EPS Next 3Y23.27%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MLND!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Millendo Therapeutics Inc

NASDAQ:MLND (6/25/2021, 8:00:01 PM)

After market: 1.06 0 (0%)

1.06

-0.06 (-5.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.92%
Ins Owner Change0%
Market Cap20.19M
Revenue(TTM)N/A
Net Income(TTM)-32.80M
Analysts0
Price Target2.04 (92.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB N/A
EV/EBITDA 0.22
EPS(TTM)-1.73
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS1.35
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -103.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.39
Quick Ratio N/A
Altman-Z -11.67
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.31%
EPS Next Y33.23%
EPS Next 2Y32.4%
EPS Next 3Y23.27%
EPS Next 5Y17.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Millendo Therapeutics Inc / MLND FAQ

What is the ChartMill fundamental rating of Millendo Therapeutics Inc (MLND) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MLND.


What is the valuation status of Millendo Therapeutics Inc (MLND) stock?

ChartMill assigns a valuation rating of 3 / 10 to Millendo Therapeutics Inc (MLND). This can be considered as Overvalued.


How profitable is Millendo Therapeutics Inc (MLND) stock?

Millendo Therapeutics Inc (MLND) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for MLND stock?

The Earnings per Share (EPS) of Millendo Therapeutics Inc (MLND) is expected to grow by 33.23% in the next year.